- 産業: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.
Industry:Pharmaceutical
A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.
Industry:Pharmaceutical
A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation.
Industry:Pharmaceutical
A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab labeled with the radioisotope zirconium Z 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89 cetuximab binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), allowing the imaging and quantification of EGFR-expressing tumor cells. EGFR is a tyrosine kinase that may be overexpressed on the cell surfaces of various tumor cell types.
Industry:Pharmaceutical
A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab conjugated with the gamma-emitting radioisotope indium In 111. Indium I 111 bevacizumab binds to vascular endothelial growth factor (VEGF), allowing the detection of VEGF distribution using gamma scintigraphy.
Industry:Pharmaceutical
A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium Zr 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89 bevacizumab targets and binds to the extracellular domain of the vascular endothelial growth factor receptor (VEGFR). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), allowing the imaging and quantification of VEGFR-expressing tumor cells. VEGFR, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.
Industry:Pharmaceutical
A radioimmunoconjugate consisting of 3F8, a murine anti-GD2 ganglioside monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic properties. Using monoclonal antibody 3F8 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing GD2. GD2 is a ganglioside which is overexpressed in malignant melanoma, neuroblastoma, and small cell carcinoma of the lung.
Industry:Pharmaceutical
A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against the extracellular domain of prostate-specific membrane antigen linked to a beta-emitting radioisotope (lutetium-177). This radioimmunoconjugate binds to tumor cells that express the extracellular domain of prostate-specific membrane antigen, delivering beta particle radiation selectively to tumor cells expressing this antigen and so limiting the exposure of normal tissues to ionizing radiation.
Industry:Pharmaceutical
A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.
Industry:Pharmaceutical
A radioimmunoconjugate consisting of a murine IgG2a monoclonal antibody directed against the human epidermal growth factor receptor (EGFR) labeled with iodine I 125 with potential antineoplastic activity. Iodine I 125 anti-EGFR-425 monoclonal antibody binds specifically to the epidermal growth factor receptor (EGFR). Upon binding to EGFR-expressing tumor cells, this agent is internalized, selectively delivering a potentially cytotoxic dose of gamma radiation. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various solid tumors.
Industry:Pharmaceutical
